CRMD Q2 2025 Earnings — CorMedix Inc. Revenue & Financial Results | Market Cap Arena

CRMDCorMedix Inc.

$536M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M+4829.4% YoY

Gross Profit

$38M95.3% margin

Operating Income

$20M49.2% margin

Net Income

$20M49.9% margin

EPS (Diluted)

$0.28

QoQ Revenue Growth

+1.7%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$30M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$253M

Total Liabilities

$32M

Stockholders' Equity

$221M

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$806,119	+4829.4%
Gross Profit	$38M	$296,280	+12683.3%
Operating Income	$20M	-$15M	+227.7%
Net Income	$20M	-$14M	+240.1%